Conference Coverage

Lenalidomide branches out to lymphoma therapy

Publish date: January 25, 2013

 

AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY

Both Dr. Chiappella’s and Dr. Goy’s studies were supported in part by Celgene, maker of lenalidomide. Dr. Chiappella reported having no relevant disclosures. Dr. Goy is on Celgene’s speakers bureau.

Pages

Recommended Reading

ASH12: New Proteasome Inhibitor Shines In All-Oral Myeloma Regimen
MDedge Hematology and Oncology
ASH12: New Myeloma Drug Works Better with Low-Dose Dexamethasone
MDedge Hematology and Oncology
Targeting new myeloma pathway pays off with ARRY-520
MDedge Hematology and Oncology
Pomalidomide: A new option for relapsed myeloma
MDedge Hematology and Oncology
TOPPS: Limit prophylactic platelets to select groups
MDedge Hematology and Oncology
MLN9708 regimen effective with reduced neuropathy risk in multiple myeloma
MDedge Hematology and Oncology
Live from ASH: Dr. David Henry shares his 'did you know' picks
MDedge Hematology and Oncology
Did you know: Dr. David Henry reports from ASH
MDedge Hematology and Oncology
Variation by age in neutropenic complications among patients with cancer receiving chemotherapy
MDedge Hematology and Oncology
Plasmablastic lymphoma presenting as proptosis and impending visual loss
MDedge Hematology and Oncology